Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAR-T cell therapy is a promising immunotherapy that uses genetically engineered T cells to recognize and destroy cancer cells. However, there are challenges with this therapy, including limited effectiveness in solid tumors and the potential for relapse. To address these, researchers are exploring combination strategies with other immunotherapies, such as vaccines, to boost the efficacy of CAR-T cell therapy. Vaccines work by stimulating the immune system to recognize and attack specific targets, such as cancer cells. The combination of CAR-T cell therapy with vaccines can enhance the targeting and killing of cancer cells of CAR-T cells, as well as boost the memory and persistence of CAR-T cells within the body. This combination approach may also help to target a broader range of cancer antigens, reducing the risk of tumor escape.
Fig.1 The mechanism of amph-vax boosting CAR-T cells.1
Various vaccines are designed to stimulate the immune system and enhance the efficacy of CAR-T cell therapy. At Creative Biolabs, we aim to provide solutions that optimize the therapeutic potential of this innovative combination treatment approach. Our team of experts is committed to delivering high-quality vaccines tailored to meet the specific needs of CAR-T cell therapy.
Peptide-DC vaccine is a type of therapeutic cancer vaccine that involves using DCs loaded with tumor-specific peptides that are presented on MHC molecules to activate CAR-T cells and enhance their ability to recognize and target cancer cells that express the specific tumor peptides. Our service involves the development and production of peptide-DC vaccines for boosting pMHC-directed CAR-T cell therapy. Our peptide-DC vaccine services include peptide selection, DC loading optimization, quality control, and functional analysis in vitro and in vivo.
Amph-ligands contain antigens to activate the CAR-T cells and long tails of lipids to bind to free albumin in the blood. Amph-ligands have been successfully used as a tumor vaccine-boosting strategy in the treatment of CAR-T cells. At Creative Biolabs, we are committed to developing innovative amph-ligand vaccines to enhance the potency of CAR-T cell therapies.
RNA vaccines can stimulate the immune system to recognize and attack cancer cells by delivering tumor-specific antigens encoded in RNA. By delivering stimulatory signals to CAR-T cells, RNA vaccines can enhance their ability to kill cancer cells and overcome mechanisms of immune evasion. At Creative Biolabs, our experts offer customized RNA vaccines for boosting CAR-T cells, making them a promising option for personalized cancer treatment.
Virus-based vaccines use a live-attenuated or inactivated virus to trigger an immune response in the body. Combining virus-based vaccines with CAR-T cell therapy may help enhance the immune response and improve the overall efficacy of the CAR-T cells.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
